InflaRx NV (IFRX)
0.8947
+0.02
(+2.51%)
USD |
NASDAQ |
Feb 20, 16:00
0.89
0.00 (0.00%)
After-Hours: 20:00
InflaRx SG&A Expense (Quarterly) : 4.427M for Sept. 30, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| CDT Equity, Inc. | 5.501M |
| LENZ Therapeutics, Inc. | 27.60M |
| Liminatus Pharma, Inc. | 0.7012M |
| Oruka Therapeutics, Inc. | 5.117M |
| Maze Therapeutics, Inc. | 7.775M |